$NURO
NeuroMetrix, Inc.

2024 Q3 Form 10-Q Financial Statement

#000162828024035221 Filed on August 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $587.3K $769.1K
YoY Change -51.19% -53.55%
Cost Of Revenue $275.4K $277.2K
YoY Change -34.65% -48.33%
Gross Profit $312.0K $491.9K
YoY Change -60.1% -56.05%
Gross Profit Margin 53.12% 63.96%
Selling, General & Admin $1.754M $2.054M
YoY Change -18.41% 3.24%
% of Gross Profit 562.34% 417.48%
Research & Development $299.7K $266.9K
YoY Change -49.42% -64.57%
% of Gross Profit 96.08% 54.26%
Depreciation & Amortization $24.52K $24.91K
YoY Change 145.2% 143.74%
% of Gross Profit 7.86% 5.06%
Operating Expenses $2.054M $2.321M
YoY Change -25.11% -15.39%
Operating Profit -$1.742M -$1.829M
YoY Change -11.16% 12.64%
Interest Expense $8.410K $13.01K
YoY Change -71.97%
% of Operating Profit
Other Income/Expense, Net $233.8K $340.7K
YoY Change 37.54% 294.22%
Pretax Income -$1.508M -$1.488M
YoY Change -14.79% -3.19%
Income Tax
% Of Pretax Income
Net Earnings -$1.508M -$1.488M
YoY Change -14.73% -3.19%
Net Earnings / Revenue -256.8% -193.45%
Basic Earnings Per Share -$0.75 -$0.74
Diluted Earnings Per Share -$0.75 -$0.74
COMMON SHARES
Basic Shares Outstanding 2.026M shares 2.011M shares
Diluted Shares Outstanding 2.023M shares 2.001M shares

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.83M $16.43M
YoY Change -15.9% -16.29%
Cash & Equivalents $921.5K $1.607M
Short-Term Investments $13.91M $14.82M
Other Short-Term Assets $381.9K $315.7K
YoY Change -51.66% -4.78%
Inventory $1.430M $1.450M
Prepaid Expenses
Receivables $149.1K $280.6K
Other Receivables $0.00 $0.00
Total Short-Term Assets $16.80M $18.48M
YoY Change -18.88% -17.11%
LONG-TERM ASSETS
Property, Plant & Equipment $219.1K $243.6K
YoY Change -19.69% -46.77%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $26.40K $26.40K
YoY Change 0.0% 0.0%
Total Long-Term Assets $393.3K $453.2K
YoY Change -32.32% -6.38%
TOTAL ASSETS
Total Short-Term Assets $16.80M $18.48M
Total Long-Term Assets $393.3K $453.2K
Total Assets $17.19M $18.93M
YoY Change -19.25% -16.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $347.6K $314.0K
YoY Change 54.18% 73.04%
Accrued Expenses $719.6K $1.127M
YoY Change -18.83% 9.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.210M $1.590M
YoY Change -4.01% 31.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $28.21K
YoY Change -100.0% -81.46%
Total Long-Term Liabilities $0.00 $28.21K
YoY Change -100.0% -81.46%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.210M $1.590M
Total Long-Term Liabilities $0.00 $28.21K
Total Liabilities $1.210M $1.618M
YoY Change -12.53% 18.79%
SHAREHOLDERS EQUITY
Retained Earnings -$216.1M -$214.6M
YoY Change 3.68% 3.84%
Common Stock $203.00 $202.00
YoY Change -76.37% -76.46%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $15.98M $17.31M
YoY Change
Total Liabilities & Shareholders Equity $17.19M $18.93M
YoY Change -19.25% -16.88%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.508M -$1.488M
YoY Change -14.73% -3.19%
Depreciation, Depletion And Amortization $24.52K $24.91K
YoY Change 145.2% 143.74%
Cash From Operating Activities -$1.792M -$1.364M
YoY Change -12.99% -5.97%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $1.107M $1.709M
YoY Change -38.5% 620.24%
Cash From Investing Activities $1.107M $1.709M
YoY Change -33.31% 620.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 2.600K
YoY Change -99.63%
NET CHANGE
Cash From Operating Activities -1.792M -1.364M
Cash From Investing Activities 1.107M 1.709M
Cash From Financing Activities 0.000 2.600K
Net Change In Cash -685.5K 347.0K
YoY Change 71.36% -167.56%
FREE CASH FLOW
Cash From Operating Activities -$1.792M -$1.364M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1487932 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537029 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
340723 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
86426 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2001400 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2001400 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
985719 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
985719 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1906927 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1906927 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
973504 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
973504 shares
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1487932 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537029 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
192712 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
102847 usd
CY2024Q2 nuro Other Comprehensive Income Realized Gain Adjustment
OtherComprehensiveIncomeRealizedGainAdjustment
327718 usd
nuro Other Comprehensive Income Realized Gain Adjustment
OtherComprehensiveIncomeRealizedGainAdjustment
532973 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1622938 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1434182 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4645506 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2942482 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
20091317 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
216164 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1471099 usd
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
212261 usd
CY2024Q1 nuro Other Comprehensive Income Realized Gain Adjustment
OtherComprehensiveIncomeRealizedGainAdjustment
205255 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3029574 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18756012 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
176148 usd
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2601 usd
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
192712 usd
CY2024Q2 nuro Other Comprehensive Income Realized Gain Adjustment
OtherComprehensiveIncomeRealizedGainAdjustment
327718 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
23355687 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
165361 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
65874 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1574174 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
22012748 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
132745 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
691405 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
8713 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
102847 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537029 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
21411429 usd
us-gaap Profit Loss
ProfitLoss
-4517506 usd
us-gaap Profit Loss
ProfitLoss
-3111203 usd
us-gaap Depreciation
Depreciation
49815 usd
us-gaap Depreciation
Depreciation
20444 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
66990 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
58087 usd
us-gaap Share Based Compensation
ShareBasedCompensation
392312 usd
us-gaap Share Based Compensation
ShareBasedCompensation
298106 usd
nuro Inventory Charge Cost Of Revenues
InventoryChargeCostOfRevenues
74209 usd
nuro Inventory Charge Cost Of Revenues
InventoryChargeCostOfRevenues
63420 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
0 usd
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
131127 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
532973 usd
us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-238258 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
99954 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-34814 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
32418 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-463377 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-254015 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
98491 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-186620 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
250620 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
350137 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-64275 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-55373 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3445868 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2572486 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
18652804 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
16599705 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
20500000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities
16000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1847196 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-599705 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1473700 usd
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
700120 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1473700 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
700120 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-124972 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2472071 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1731946 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4335020 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1606974 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1862949 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
16400000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
25000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Debt Securities Held To Maturity Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
0 usd
CY2023Q4 us-gaap Debt Securities Held To Maturity Allowance For Credit Loss
DebtSecuritiesHeldToMaturityAllowanceForCreditLoss
0 usd
us-gaap Use Of Estimates
UseOfEstimates
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during reporting periods. Actual results could differ from those estimates.</span></div>
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-135006 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-128000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1487932 usd
us-gaap Net Income Loss
NetIncomeLoss
-4517506 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-102847 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-168721 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537029 usd
us-gaap Net Income Loss
NetIncomeLoss
-3111203 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1487932 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1537029 usd
us-gaap Net Income Loss
NetIncomeLoss
-4517506 usd
us-gaap Net Income Loss
NetIncomeLoss
-3111203 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2001400 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2001400 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
985719 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
985719 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1906927 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1906927 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
973504 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
973504 shares
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.74
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.74
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.56
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.20
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
175529 shares
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
90170 shares
CY2023Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
0 usd
CY2024Q2 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
0 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
14710811 usd
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
112171 usd
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
14822982 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
16025034 usd
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
240171 usd
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
16265205 usd
CY2024Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
16120040 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
17549495 usd
CY2024Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1129688 usd
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1151381 usd
CY2024Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
320717 usd
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
408047 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
1450405 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1559428 usd
nuro Inventory Charge Cost Of Revenues
InventoryChargeCostOfRevenues
74209 usd
nuro Inventory Charge Cost Of Revenues
InventoryChargeCostOfRevenues
63420 usd
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
610840 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
298534 usd
CY2024Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
107410 usd
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
346245 usd
CY2024Q2 us-gaap Restructuring Reserve
RestructuringReserve
221000 usd
CY2023Q4 us-gaap Restructuring Reserve
RestructuringReserve
0 usd
CY2024Q2 nuro Accrued Clinical Current
AccruedClinicalCurrent
19891 usd
CY2023Q4 nuro Accrued Clinical Current
AccruedClinicalCurrent
39000 usd
CY2024Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
8000 usd
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
9400 usd
CY2024Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
132708 usd
CY2023Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
141672 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27510 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
41888 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1127359 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
876739 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
82892 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
117431 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200323 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.15
CY2024Q2 nuro Operating Lease Discount
OperatingLeaseDiscount
23722 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
148391 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
28210 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
200323 usd
CY2024Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
50377 usd
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
49232 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
100754 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
98464 usd
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M12D
CY2024Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
10
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001628280-24-035221-index-headers.html Edgar Link pending
0001628280-24-035221-index.html Edgar Link pending
0001628280-24-035221.txt Edgar Link pending
0001628280-24-035221-xbrl.zip Edgar Link pending
a10q63024exhibit311.htm Edgar Link pending
a10q63024exhibit312.htm Edgar Link pending
a10q63024exhibit32.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nuro-20240630.htm Edgar Link pending
nuro-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nuro-20240630_cal.xml Edgar Link unprocessable
nuro-20240630_def.xml Edgar Link unprocessable
nuro-20240630_lab.xml Edgar Link unprocessable
nuro-20240630_pre.xml Edgar Link unprocessable
nuro-20240630_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable